Degradation Byproduct Characterisation

Degradation byproduct characterisation systematically identifies, quantifies, and assesses safety implications of pharmaceutical product decomposition products arising during manufacturing, storage, and use. Stress testing under accelerated conditions including elevated temperature, humidity, light, and pH conditions produces representative degradation profiles. Analytical techniques including high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance structure identification of major and minor degradation products. Regulatory submissions require comprehensive byproduct characterisation justifying acceptability limits.

Toxicological assessment of identified degradation products determines whether specific testing requirements apply or general impurity limits suffice. Genotoxic or pharmacologically active byproducts require enhanced monitoring. Manufacturing process optimisation reduces degradation product formation through improved stability. Container-closure systems and packaging modifications minimise environmental stress exposure. Real-time stability monitoring throughout shelf life detects unexpected degradation patterns prompting investigation. Regulatory actions have resulted from inadequate byproduct characterisation allowing toxic decomposition products accumulation.